01541.HK
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 3.40
+0.29%Margins
Gross margin
97.0%
EBITDA margin
-182.9%
EBIT margin
-187.7%
Net margin
-193.0%
FCF margin
-78.0%
-84.6%
Return on equity
-51.4%
Return on assets
-52.1%
Return on invested capital
0.26x
Asset turnover
-HKD 243.1M
Cash from operations
HKD 2.67
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026